{
    "nct_id": "NCT03755102",
    "official_title": "A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progressionon Osimertinib.",
    "inclusion_criteria": "* Written informed consent\n* Advanced biopsy-proven metastatic non-small cell lung cancer\n* Somatic activating mutation in EGFR in a tumor biopsy or plasma cfDNA liquid biopsy\n* Prior treatment with osimertinib with response followed by disease progression\n* No prior first or second generation EGFR inhibitor treatment (gefitinib, afatinib, erlotinib)\n* Archival tissue available from a tumor biopsy done after disease progression on osimertinib or willing to undergo a tumor biopsy or liquid biopsy after disease progression on osimertinib prior to study initiation\n* Measurable (RECIST 1.1) indicator lesion not previously irradiated\n* Karnofsky performance status (KPS) >/= 70%\n* Age >/= 18 years old\n* Ability to swallow oral medication\n* Adequate organ function\n\n  * AST, ALT </= 3 x ULN\n  * Total bilirubin </= 1.5x ULN\n  * Creatinine </= 1.5x ULN OR calculated creatinine clearance >/= 60ml/min\n  * Absolute neutrophil count (ANC) >/= 1000 cells/mm3\n  * Hemoglobin>/=8.0 g/dL\n  * Platelets >/=75,000/mm3\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or lactating women\n* Any radiotherapy within 1 week of starting treatment on protocol.\n* Any major surgery within 1 weeks of starting treatment on protocol.\n* Any evidence of active clinically significant interstitial lung disease\n* Continue to have unresolved > grade 1 toxicity from any previous treatment Treatment\n* Patients with a known mechanism of resistance to osimertinib that will clearly not respond to dacomitinib therapy (i.e. known MET amplification, ALK fusion, RET fusion).\n* Symptomatic brain metastases or leptomeningeal disease requiring escalating doses of steroids",
    "miscellaneous_criteria": ""
}